{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:56Z","timestamp":1792003556203,"version":"4.4.0"},"reference-count":35,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OPTH"],"DOI":"10.2147\/opth.s367089","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T02:55:09Z","timestamp":1674442509000},"page":"321-327","source":"Crossref","is-referenced-by-count":61,"title":["Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration"],"prefix":"10.2147","volume":"Volume 17","author":[{"given":"Hannah","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-4861","authenticated-orcid":true,"given":"Aamir A","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-2097","authenticated-orcid":true,"given":"Humza","family":"Sulahria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0419-5565","authenticated-orcid":true,"given":"Abrahim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netan","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Danzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-5599","authenticated-orcid":true,"given":"Arshad M","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000066507","volume":"49","author":"Harvey","year":"2003","journal-title":"Gerontology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0039-6257(88)90052-5","volume":"32","author":"Bressler","year":"1988","journal-title":"Surv Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"483960","DOI":"10.1155\/2014\/483960","volume":"2014","author":"Kawa","year":"2014","journal-title":"J Immunol Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3390\/ijms20071693","volume":"20","author":"Nebbioso","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajo.2014.04.016","volume":"158","author":"Chiu","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejphar.2016.03.001","volume":"787","author":"Xu","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3345\/kjp.2015.58.7.239","volume":"58","author":"Cho","year":"2015","journal-title":"Korean J Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"ref12","unstructured":"Iveric Bio. Iveric Bio announces positive Zimura 18 month data supporting the 12 month efficacy findings: continuous positive treatment effect with favorable safety profile in geographic atrophy secondary to age-related macular degeneration in a phase 3 trial; 2020. Available from: https:\/\/investors.ivericbio.com\/news-releases\/news-release-details\/iveric-bio-announces-positive-zimura-18-month-data-supporting-12. Accessed October 20, 2021."},{"key":"ref13","unstructured":"ClinicalTrials.gov. A phase I study of ARC1905 (anti-C5 aptamer) in subjects with dry age-related macular degeneration. ClinicalTrials.gov Identifier: NCT00950638. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00950638. Accessed January 10, 2023."},{"key":"ref14","unstructured":"Rezaei K A method for treating or preventing neovascular age-related macular degeneration. W O 2019\/040397 A l ed: World Intellectual Property Organization \u2013 International Bureau; 2019."},{"key":"ref15","unstructured":"Iveric Bio I. Iveric bio announces positive zimura 18 month data supporting the 12 month efficacy findings: continuous positive treatment effect with favorable safety profile in geographic atrophy secondary to age-related macular degeneration in a phase 3 trial; 2020. Available from: https:\/\/investors.ivericbio.com\/news-releases\/news-release-details\/iveric-bio-announces-positive-zimura-18-month-data-supporting-12. Accessed January 10, 2023."},{"key":"ref16","unstructured":"ClinicalTrials.gov. A phase 3 safety and efficacy study of intravitreal administration of Zimura (complement C5 inhibitor) ClinicalTrials.gov identifier: NCT04435366. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435366. Accessed January 10, 2023."},{"key":"ref17","first-page":"1","volume":"2022","author":"Khanani","year":"2022","journal-title":"Am Acad Ophthalmol"},{"key":"ref18","unstructured":"ClinicalTrials.gov. A phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA). ClinicalTrials.gov Identifier: NCT02503332. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02503332. Accessed January 10, 2023."},{"key":"ref19","unstructured":"Heier J, Wykoff C, Singh R, et al. Efficacy of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials. Retina Society; 2021. Available from: https:\/\/investors.apellis.com\/static-files\/fe6d8c27-e1b2-4c87-b77f-aa5cb249bacf. Accessed January 10, 2023."},{"key":"ref20","unstructured":"NGM bio announces topline results from the CATALINE phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration; 2022. Available from: https:\/\/ir.ngmbio.com\/node\/9586\/pdf. Accessed January 10, 2023."},{"key":"ref21","unstructured":"ClinicalTrials.gov. Safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy due to age-related macular degeneration (AMD) ClinicalTrials.gov identifier: NCT00658619. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00658619. Accessed January 10, 2023."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4103\/2008-322X.183923","volume":"11","author":"Doozandeh","year":"2016","journal-title":"J Ophthalmic Vis Res"},{"key":"ref23","unstructured":"ClinicalTrials.gov. Safety and efficacy of brimonidine posterior segment drug delivery system in patients with geographic atrophy secondary to age-related macular degeneration clinicaltrials.gov identifier: NCT02087085. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02087085. Accessed January 10, 2023."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/IAE.0000000000002789","volume":"41","author":"Kuppermann","year":"2021","journal-title":"Retina"},{"key":"ref25","first-page":"971","volume":"60","author":"Freeman","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref26","unstructured":"Waheed NK FOCUS interim results: GT005 gene therapy phase I\/II study for the treatment of geographic atrophy. angiogenesis, exudation, and degeneration; 2021. Available from: https:\/\/www.gyroscopetx.com\/wp-content\/uploads\/2021\/02\/Waheed-Focus_FINAL.pdf. Accessed January 10, 2023."},{"key":"ref27","unstructured":"ClinicalTrials.gov. Focus: first in human study to evaluate the safety and efficacy of GT005 administered in subjects with dry AMD\u201d clinicaltrials.gov identifier: NCT03846193. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03846193. Accessed January 10, 2023."},{"key":"ref28","first-page":"1504","volume":"6`","author":"Nielsen","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref29","unstructured":"ClinicalTrials.gov. HORIZON: a Phase II study to evaluate the safety and efficacy of two doses of GT005. ClinicalTrials.gov Identifier: NCT04566445. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04566445. Accessed January 10, 2023."},{"key":"ref30","unstructured":"ClinicalTrials.gov. EXPLORE: a phase II study to evaluate the safety and efficacy of two doses of GT005. ClinicalTrials.gov Identifier: NCT04437368. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04437368. Accessed January 10, 2023."},{"key":"ref31","unstructured":"ClinicalTrials.gov. A phase 1, open-label, multi-center, dose-escalating, safety and tolerability study of a single intravitreal injection of AAVCAGsCD59 in patients with advanced non-exudative (dry) age-related macular degeneration with geographic atrophy. ClinicalTrials.gov Identifier: NCT03144999. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03144999. Accessed January 10, 2023."},{"key":"ref32","unstructured":"Dugel PU Data on a gene therapy for dry and wet AMD A phase 1 clinical trial program is targeting both disease states. Available from: https:\/\/www.retinalphysician.com\/issues\/2020\/april-2020\/clinical-trial-download-data-on-a-gene-therapy-for. Accessed January 10, 2023."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.scr.2012.05.002","volume":"9","author":"Cho","year":"2012","journal-title":"Stem Cell Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/08820538.2011.577498","volume":"263","author":"Du","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"ref35","unstructured":"ClinicalTrials.gov. Safety and efficacy study of opregen for treatment of advanced dry-form age-related macular degeneration clinicalTrials.gov identifier: NCT02286089. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02286089. Accessed January 10, 2023."}],"container-title":["Clinical Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87010","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T02:55:36Z","timestamp":1674442536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/emerging-treatment-options-for-geographic-atrophy-ga-secondary-to-age--peer-reviewed-fulltext-article-OPTH"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2147\/opth.s367089","relation":{},"ISSN":["1177-5483"],"issn-type":[{"value":"1177-5483","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}